<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306096</url>
  </required_header>
  <id_info>
    <org_study_id>SCANB001</org_study_id>
    <nct_id>NCT02306096</nct_id>
  </id_info>
  <brief_title>Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer</brief_title>
  <acronym>SCAN-B</acronym>
  <official_title>SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Sweden Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mrs. Berta Kamprad Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>U-CAN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the genomic profiles of breast cancer in a prospective and
      population-based manner. In the first phase, breast tumors are analyzed by whole
      transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript
      isoform-level data will be analyzed in the context of patient information,
      clinicopathological variables, and outcome, with the purpose to develop new molecular
      diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses
      will be performed in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer exhibits significant molecular, pathological, and clinical heterogeneity.
      Current patient and clinicopathological evaluation is imperfect for predicting outcome, which
      results in overtreatment for many patients, and for others, leads to death from recurrent
      disease. Therefore, additional criteria are needed to better personalize care and maximize
      treatment effectiveness and survival.

      The Sweden Cancerome Analysis Network - Breast (SCAN-B) study was initiated in 2010 as a
      multicenter prospective population-based observational study with longsighted aims to analyze
      breast cancers with next-generation genomic technologies for translational research and
      integrated with healthcare; decipher fundamental tumor biology from these analyses; utilize
      genomic data to develop and validate new clinically-actionable biomarker assays; and
      establish real-time clinical implementation of molecular diagnostic, prognostic, and
      predictive tests. In the first phase, we focus on molecular profiling by next-generation
      RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level
      data will be analyzed in the context of patient information, clinicopathological variables,
      and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer.
      Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.

      As of June 2020, over 15,000 patients have enrolled in the study, representing approximately
      85% of all eligible patients within the catchment region. Tissue and blood collection is
      integrated within healthcare routines and clinical information is provided from national
      quality registries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2031</completion_date>
  <primary_completion_date type="Anticipated">August 2031</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers and clinicopathological information</measure>
    <time_frame>up to 20-years</time_frame>
    <description>Analysis of genomic data (biomarkers) and their relationship to patient and tumor clinicopathological information; assessment of analytical validity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive disease-free survival</measure>
    <time_frame>up to 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of IDFS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-years, 5-years, 10-years, 15-years, 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of OS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific survival</measure>
    <time_frame>3-years, 5-years, 10-years, 15-years, 20-years</time_frame>
    <description>Different biomarkers will be analysed in the context of BCS at different time-points for different subgroups of the prospective cohort, for example for all patients receiving a particular therapy or patients with tumors of a specific molecular subtype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>intraoperative</time_frame>
    <description>Different biomarkers will be analysed in the context of pathological response at time of surgery for patients receiving pre-operative therapy.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Breast Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue, whole blood, serum, plasma. Collected at diagnosis and during follow-up.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with suspected or confirmed diagnosis of primary breast cancer within
        participating hospital systems in the South Sweden Healthcare Region, Uppsala County, and
        Jönköping Country, Sweden. Additional hospital sites from within the Nordic countries are
        welcome to join.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicion or confirmed diagnosis of primary breast cancer

          -  signed informed consent

        Exclusion Criteria:

          -  lack of signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åke Borg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia Hegardt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christer Larsson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niklas Loman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Malmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Ehinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Rydén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lao H Saal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Åke Borg, PhD</last_name>
    <phone>+46-46-2752552</phone>
    <email>ake.borg@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Malmberg, MD, PhD</last_name>
    <email>martin.malmberg@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallands Hospital Halmstad</name>
      <address>
        <city>Halmstad</city>
        <zip>30233</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Åhlund, MD</last_name>
      <email>lars.ahlund@regionhalland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <zip>25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Karin Falck, MD</last_name>
      <email>anna-karin.falck@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kirurgiska kliniken</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bengt Asking, MD</last_name>
      <phone>+46-36-321353</phone>
      <email>bengt.asking@rjl.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blekinge County Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Sjövall, MD</last_name>
      <email>monika.sjovall@ltblekinge.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <zip>29185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tor Svensjö, MD, PhD</last_name>
      <email>tor.svensjo@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Rydén, MD PhD</last_name>
      <phone>+46-46-176241</phone>
      <email>lisa.ryden@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Rehn, MD, PhD</last_name>
      <phone>+46-40-331892</phone>
      <email>martin.rehn@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Sjöblom, PhD</last_name>
      <phone>+46-18-4715036</phone>
      <email>tobias.sjoblom@igp.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Växjö</name>
      <address>
        <city>Växjö</city>
        <zip>35234</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Weber, MD</last_name>
      <phone>+46-470-588052</phone>
      <email>per.weber@ltkronoberg.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.med.lu.se/english/scan_b</url>
    <description>Sweden Cancerome Analysis Network - Breast (SCAN-B) Website (Lund University)</description>
  </link>
  <link>
    <url>https://www.scan-b.lu.se</url>
    <description>Sweden Cancerome Analysis Network - Breast (SCAN-B) Website (Lund University) [SWEDISH LANGUAGE]</description>
  </link>
  <reference>
    <citation>Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, Lindman H, Ehinger A, Saal LH, Borg Å. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg. 2018 Jan;105(2):e158-e168. doi: 10.1002/bjs.10741.</citation>
    <PMID>29341157</PMID>
  </reference>
  <results_reference>
    <citation>Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015 Feb 2;7(1):20. doi: 10.1186/s13073-015-0131-9. eCollection 2015.</citation>
    <PMID>25722745</PMID>
  </results_reference>
  <results_reference>
    <citation>Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019 Oct;25(10):1526-1533. doi: 10.1038/s41591-019-0582-4. Epub 2019 Sep 30.</citation>
    <PMID>31570822</PMID>
  </results_reference>
  <results_reference>
    <citation>Vallon-Christersson J, Häkkinen J, Hegardt C, Saal LH, Larsson C, Ehinger A, Lindman H, Olofsson H, Sjöblom T, Wärnberg F, Ryden L, Loman N, Malmberg M, Borg Å, Staaf J. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Sci Rep. 2019 Aug 21;9(1):12184. doi: 10.1038/s41598-019-48570-x.</citation>
    <PMID>31434940</PMID>
  </results_reference>
  <results_reference>
    <citation>Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg Å, Staaf J, Rydén L. Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clin Cancer Res. 2019 Nov 1;25(21):6368-6381. doi: 10.1158/1078-0432.CCR-19-0075. Epub 2019 Jul 24.</citation>
    <PMID>31340938</PMID>
  </results_reference>
  <results_reference>
    <citation>Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Res Treat. 2019 Nov;178(2):459-467. doi: 10.1007/s10549-019-05378-7. Epub 2019 Aug 20.</citation>
    <PMID>31432367</PMID>
  </results_reference>
  <results_reference>
    <citation>Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl PO, Manjer J, Malmberg M, Larsson C, Loman N, Rydén L, Borg Å, and Saal LH. Clinical Value of RNA Sequencing-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. JCO Precision Oncology 2018 :2, 1-18. http://dx.doi.org/10.1200/PO.17.00135</citation>
  </results_reference>
  <results_reference>
    <citation>Søkilde R, Persson H, Ehinger A, Pirona AC, Fernö M, Hegardt C, Larsson C, Loman N, Malmberg M, Rydén L, Saal L, Borg Å, Vallon-Christerson J, Rovira C. Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics. 2019 Jun 17;20(1):503. doi: 10.1186/s12864-019-5887-7.</citation>
    <PMID>31208318</PMID>
  </results_reference>
  <results_reference>
    <citation>Persson H, Søkilde R, Häkkinen J, Pirona AC, Vallon-Christersson J, Kvist A, Mertens F, Borg Å, Mitelman F, Höglund M, Rovira C. Frequent miRNA-convergent fusion gene events in breast cancer. Nat Commun. 2017 Oct 5;8(1):788. doi: 10.1038/s41467-017-01176-1.</citation>
    <PMID>28983113</PMID>
  </results_reference>
  <results_reference>
    <citation>Persson H, Søkilde R, Häkkinen J, Vallon-Christersson J, Mitelman F, Borg Å, Höglund M, Rovira C. Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer. Int J Cancer. 2020 Jun 15;146(12):3343-3353. doi: 10.1002/ijc.32927. Epub 2020 Feb 28.</citation>
    <PMID>32067223</PMID>
  </results_reference>
  <results_reference>
    <citation>Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016 Aug;27(8):1532-8. doi: 10.1093/annonc/mdw209. Epub 2016 May 18.</citation>
    <PMID>27194814</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Åke Borg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prognostic and predictive biomarkers</keyword>
  <keyword>RNA-sequencing</keyword>
  <keyword>pathological complete response</keyword>
  <keyword>minimal residual disease</keyword>
  <keyword>molecular subtype</keyword>
  <keyword>gene expression profiling</keyword>
  <keyword>mutation screening</keyword>
  <keyword>BRCA</keyword>
  <keyword>translational research</keyword>
  <keyword>genomics</keyword>
  <keyword>transcriptomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>metabolomics</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>circulating tumor cells</keyword>
  <keyword>circulating tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon publication, the relevant anonymized individual participant data will be shared.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>GSE60789</doc_id>
      <doc_type>RNA-seq Processed Gene Expression Data and Annotations</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60789</doc_url>
      <doc_comment>SuperSeries: GSE60789 SubSeries: GSE60785, GSE60788</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

